Novel approaches for HTLV-1 therapy: innovative applications of CRISPR-Cas9
Rev. Inst. Med. Trop. São Paulo (Online)
; 66: e48, 2024. graf
Article
in En
|
LILACS-Express
| LILACS
| ID: biblio-1569553
Responsible library:
BR1.1
ABSTRACT
ABSTRACT The human T-cell lymphotropic virus type 1 (HTLV-1) is a single-stranded positive-sense RNA virus that belongs to the Retroviridae family, genus Deltaretro, and infects approximately five to 10 million people worldwide. Although a significant number of individuals living with HTLV-1 remain asymptomatic throughout their lives, some develop one or more severe clinical conditions, such as HTLV-1-associated myelopathy/tropical spastic paraparesis (HAM/TSP), a progressive and debilitating disease, and/or a subtype of non-Hodgkin's lymphoma with a more threatening course known as adult T-cell leukemia/lymphoma (ATLL). Moreover, current therapeutic options are limited and focus primarily on treating symptoms and controlling viral latency. CRISPR-Cas9 gene editing is proposed as a promising tool to address the intricate links associated with HTLV-1. By targeting or silencing key genes during initial infection and dysregulating immune signaling pathways, CRISPR-Cas9 offers potential intervention opportunities. In this review, we address the therapeutic potential of CRISPR-Cas9 gene editing, as well as examine the primary mechanisms involved in editing potential target genes and discuss the existing evidence in the current scientific literature.
Full text:
1
Collection:
01-internacional
Database:
LILACS
Language:
En
Journal:
Rev. Inst. Med. Trop. São Paulo (Online)
Journal subject:
Medicina Tropical
Year:
2024
Document type:
Article
/
Project document
Affiliation country:
Brazil
Country of publication:
Brazil